Skip to main content

A Phase 3, Multinational, Multicenter, Open-Label Study of the Safety, Tolerability, Efficacy, and Pharmacokinetics of ProMetic BioTherapeutics Immune Globulin Intravenous (Human) 10% in Adults and Children with Primary Immunodeficiency Diseases.

Clinical Trial Grant
Duke Scholars

Administered By

Pediatrics, Allergy and Immunology

Awarded By

ProMetic Life Sciences Inc.

Start Date

January 1, 2017

End Date

January 31, 2020
 

Administered By

Pediatrics, Allergy and Immunology

Awarded By

ProMetic Life Sciences Inc.

Start Date

January 1, 2017

End Date

January 31, 2020